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a B S T r a c T
Bronchial thermoplasty (BT) is an innovative non-pharmacological endoscopic treatment for patients with severe persistent asthma based on 
controlled heat release with a device called Alair™ Catheter (Boston Scientific, Natick, MA, USA). The Alair™ system is the first device that 
works by delivering radiofrequency or thermal energy to selectively reduce the amount of airway smooth muscle (ASM) in bronchi. Literature 
showed significant improvement in clinical outcomes such as symptom control, severe exacerbation rate, hospitalization, quality of life, and 
number of working or school days lost for asthma. Besides smooth muscle effects changes in inflammatory pattern after BT have been docu-
mented. Bronchial thermoplasty requires an experienced physician who had a proficiency training in bronchoscopy and had rigor, dexterity and 
a thorough knowledge of the airway anatomy. Furthermore, right selection of severe asthma patient is crucial in order to have best response after 
BT. This article reviews BT device description and how to perform the procedure. criteria for right selection and management of patient before 
and after BT will be discussed.
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asthma, as defined in the Global INitiative for Asthma (Gina) 2018 document, is a heterogeneous disease, 
usually characterized by chronic airway inflammation. It 
is defined by the history of respiratory symptoms such as 
wheeze, shortness of breath, chest tightness and cough that 
vary over time and in intensity, together with variable ex-
piratory airflow limitation.1 it is a common chronic respira-
tory disease which affects in some countries up to 18% of 
the population. it is also a heterogeneous disease with dif-
ferent pathogenetic mechanisms and different clinical phe-
notypes. Patients with severe asthma represent 5-10% of all 
asthmatic population. Severe asthmatic (Sa) patient is de-
fined as a subject which requires continuous treatment with 
recommended medications for Gina step 4-5 or systemic 
corticosteroids (cS) for more of 6 months in the previous 
year, to achieve a clinical control or which remains “uncon-
trolled” despite this therapy. Uncontrolled asthma is defined 
as: 1) presence of poor symptoms control (with asthma con-
trol questionnaire or as defined by GINA guidelines); 2) fre-
quent severe exacerbation (i.e., 2 treatment with systemic 
cS) in the previous year; 3) at least one hospitalization for 
asthma; 4) persistent bronchial obstruction with a postbron-
chodilator Fev.1<80% predicted.2 Under the definition of 
“severe asthma” are included several clusters with different 
clinical presentations, underlying pathophysiological char-
acteristics and outcomes. These clusters are often called 
“asthma phenotypes.” The most common phenotypes in-
clude: allergic, non-allergic (neutrophilic, eosinophilic or 
pauci-granulocytic), late-onset, asthma with fixed airflow 
limitation, asthma with obesity. Chronic airflow limita-
tion in severe asthma (Sa) is due to the increase in airway 
wall thickness from airway remodeling caused by epithelia 
thickening, subepithelial fibrosis, airway smooth muscle 
(ASM) hypertrophy, inflammatory cell infiltration and gob-
let cell hyperplasia.2, 3 The treatments of Sa patients include 
medications recommended by Gina for step 4-5. Gina 
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• the alair™ rF catheter is a single-use device de-
signed to be brought into position using a standard bron-
choscope introduced through the nose or mouth. The 
catheter delivers controlled release radiofrequency energy 
over the entire length of the airway walls reached, with a 
pulse lasting ten seconds, causing a reduction of smooth 
muscle mass in the airways of asthmatic patients;
• alair™ rF controller is the energy generator to 
which is connected a foot switch to start an activation and 
an electrode that delivers radiofrequency which is trans-
formed into heat on contact with bronchial mucosa. Ther-
moplasty alair™ system allow the delivery of thermal en-
ergy temperature-controlled rF energy to the airway at a 
temperature of 65°c at an appropriate intensity and for a 
time sufficient to reduce the smooth muscle’s mass in the 
airway, while limiting the long-term impact on surround-
ing tissue.10
The Alair™ Catheter needs standard flexible broncho-
scope with a 4.9-5.2 mm outer diameter with a working 
channel of 2.0 mm. The electrode array is expanded to 
contact the airway walls and then activated to deliver rF 
energy over the 5 mm length of the exposed electrode. RF 
step 4 includes medium to high dose of inhaled cS (icS) 
with a long acting beta-agonist (LaBa), and/or the long 
acting antimuscarinic antagonist (Lama) tiotropium, leu-
kotriene receptor antagonist or theophylline. If the control 
is not achieved within Gina step 4, Gina step 5 includes 
icS plus tiotropium, monoclonal antibodies anti-ige, anti-
interleukin 5 (anti-IL5) and, eventually, low dose of oral 
cS. it is from a decade, with the introduction in the clinical 
practice of monoclonal antibody anti-ige, that the differen-
tiation in phenotypes has assumed practical relevance. The 
recent availability of other new monoclonal antibody anti-
interleukin 5 also extend the use of phenotyping asthmatic 
subjects. Anti-IgE can be considered in patients with a pre-
dominant allergic phenotype, and anti-iL5 in patients with 
a predominant eosinophilic phenotype.4 However, to date, 
no strong relationship has been found between specific phe-
notypes and treatment response.5 although symptoms can 
be controlled in the majority of SA patients with a pharma-
cological approach, there is a substantial group of subjects 
who remains difficult-to-treat, symptomatic, with frequent 
access to emergency room and hospitalization. These pa-
tients are also responsible for a relatively large proportion 
of total resource expenditure for asthma.6
Bronchial thermoplasty (BT) is a recently developed in-
novative bronchoscopic treatment that aim to reverse the 
process of airway remodeling in patients with Sa. The tar-
get is the aSm and is achieved by delivering controlled 
thermal radiofrequency (RF) energy to the airway small 
muscle causing a reduction in ASM contractility and quan-
tity.7 BT has been approved in 2010 by the US Food and 
drug administration for asthmatic patients aged 18 years 
and older “whose severe and persistent asthma is not well 
controlled with inhaled corticosteroids and long-acting 
beta agonist medication.”8 BT can be considered for Sa 
patients with predominant chronic airflow obstruction or 
patients with unsatisfactory response to Gina step 5, par-
ticularly those who are not eligible for anti-ige or anti-
iL5.9 It has also to be mentioned in this framework that 
Task Force on SA recommend that BT is performed only 
in the context of an Institutional Review Board-approved 
independent systematic registry or a clinical study.6
Knowledge of the instruments 
and mechanism of action
Alair™ System
The Alair™ System (Asthmatx Inc., Sunnyvale, CA, 
USA) consist of two major components, as illustrated in 
Figure 1a, B:
Figure 1.—A) Alair™ Radiofrequency (RF) Controller: designed to 
safely and accurately deliver precise, controlled rF energy through the 
catheter to the airway walls; B) Alair™ Catheter: a flexible tube with an 
expandable wire array at the tip to deliver therapeutic RF energy to the 
airway walls via a standard bronchoscope.
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loid Type 1 (TrPv1) receptors and type-c unmyelinated 
fibers known to be heat sensitive.19 TRPV1, also known as 
the capsaicin receptor, and the vanilloid receptor 1 are a 
subfamily of channel proteins that play an important role 
for cough in subjects with airway hyperresponsiveness 
(aHr).22, 23 These channel proteins, when stimulated by 
irritant agents, switch on inducing stimulation of type-c 
unmyelinated fibers in bronchial mucosa by interrupting 
central and local reflexes responsible for the activation of 
bronchospasm in presence of bronchial hyperreactivity. 
Recently, it has been demonstrated a reduction of nerve fi-
bers in epithelium and ASM. This result could explain the 
clinical improvement of patient underwent BT and support 
hypothesis previously suggested (Figure 2).24
Pretolani et al. carried out a study where they demon-
strated that BT downregulates selectively structural ab-
normalities drive airway narrowing and bronchial reac-
tivity, particularly aSm, neuroendocrine epithelial cells, 
and bronchial nerve endings.25 in detail, in a cohort of 15 
uncontrolled asthmatic patients that underwent BT, data 
showed a reduction in aSm area (median values before 
and after BT, respectively: 19.7 and 5.3%, P<0.001), sub-
epithelial basement membrane thickening (4.4 and 3.9 
µm, P<0.02), submucosal nerves (1.0, 0.7-1.3‰), aSm-
associated nerves (452.6, 196.0-811.2) immunoreactive 
pixels per mm2 and 62.7, 0.0-230.3), and epithelial neuro-
endocrine cells (4.9 and 0.0/mm2, P<0.02).
Regarding the effects of BT on inflammation, there are 
different pathways involved. doeing et al. demonstrated 
a reduction in T-cells and ranTeS/ccL5 in Broncho-
alveolar Lavage (BaL) after 3 and 6 months of BT in 
11 severe asthmatic patients, but not all patients showed 
transfer energy from the electrode to the tissue where it is 
converted into thermal energy. The correct intensity and 
duration of energy delivery is regulated by the controller 
resulting in a reduction in the amount of airway smooth 
muscle, while limiting/minimizing collateral damage to 
other airway supporting structures.
Mechanisms of action
As we know BT can functionally inactivate smooth muscle 
cells of the bronchus, but this is not enough to fully explain 
the clinical effects on patients. after 3 months of BT, au-
bier observed a selective down-regulation in aSm, neuro-
endocrine epithelial cells and nerve fibers, suggesting the 
involvement of multiple mechanisms through which BT 
can exert its effects.11 it is worth remembering that severe-
moderate asthma, concerning histological and pathological 
pathway, is characterized by an airway remodeling that in-
volves epithelial abnormalities, increased basal membrane 
thickness, changes of the interstitial matrix, increased vas-
cularization, hypertrophy of mucous glands and aSm hy-
pertrophy/hyperplasia.12, 13 Airway remodeling is known 
to be caused by chronic asthmatic inflammation. Indeed, 
inflammation is the main actor well known to be involved 
in pathogenesis of asthma. In particular, pro-inflammatory 
cytokines released at bronchial mucosal level, activate an 
inflammatory cascade that ends in deposition of extracel-
lular matrix and smooth muscle tissue hyperplasia which 
leads to airway wall thickness.14, 15 The aSm role in asth-
ma is still under investigation, but Woodfruff has clearly 
demonstrated a hyperplasia of aSm in biopsies of mild 
to moderate asthmatic patients.16 moreover, it has been 
documented, in patients died for fatal asthma, a deposition 
of collagens and myofibroblasts,17 suggesting modifica-
tion of airway function caused by these molecules.18 aSm 
seems to have also a pacemaker function for bronchial 
contractility through a nervous stimulus resulting in an in-
crease of inflammatory pathway.17 although mechanisms 
of action of BT remains under investigation, based on 
what we have discussed before, it has been supposed that 
BT could improve asthma outcome through the release of 
thermal energy to large bronchi even if asthma is known 
to be a small airways disease. indeed, literature reports re-
duction of aSm as a BT target.19 More specifically ASM 
cells could have a role of pace-maker on the downstream 
bronchi.20, 21 This hypothesis is supported by the assump-
tion that destruction of aSm induced by BT act to nerve 
fibers interrupting central and local reflexes. These results 
on bronchial wall may be due to distribution in the large 
bronchi of a number of Transient receptor Potential vanil-
Figure 2.—morphologic characterization of nerves in whole-mount air-
way biopsies.
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addressed to other therapies, or who decided to perform 
a once-lifetime therapy.28 ideal BT candidate has daily 
symptoms as measured by asthma control test (acT) and/
or ACQ, and recurrent/frequent exacerbations, which re-
sults in a major burden on their quality of life as measured 
by an asthma-related quality-of-life questionnaire (e.g., 
aQLQ).
despite the availability of several monoclonal anti-
body for severe asthma treatment, we could address to BT 
a patient who is not eligible for bio-drugs or is a non-
responder phenotype or unwilling to undergo therapies 
with an indefinite duration since BT consists of only 3 
procedure. erS/aTS guidelines currently recommend BT 
in adults with severe refractory asthma despite optimal 
therapy but only in the context of an “Institutional Review 
Board-approved independent systematic registry” or in a 
clinical study.6 Similar recommendation is given by the 
latest cochrane review, which also stresses the need for 
new studies to better understand BT mechanisms of action 
in the different asthmatic phenotypes and in patients with 
severe respiratory disturbances.29 Following these indica-
tions, the Bronchial Thermoplasty Global registry (BT 
Registry), a 2-year observational study that is expected 
to provide new and valuable data, is currently recruiting 
patients.
respiratory improvement after treatment.26 BT’s anti-
inflammatory effect has been observed in a retrospective 
review of 15 consecutive patients. Study showed a statisti-
cally and clinically significant reduction in blood eosino-
phil counts after BT treatment.27 eosinophilia were also 
observed in bronchoalveolar lavage fluid of asthma patient 
after BT, but it should to be considered that this effect was 
probably determined by the OcS administered before the 
procedure.26
Indication of procedure and selection of patient
BT has been applied both to patients with moderate-to-
severe asthma, refractory to the available optimal medi-
cal maintenance therapy, including biological drugs. The 
key selection criteria are provided in Table I. According to 
new subtypes of asthma, BT finds place in the treatment 
of T2-low subtype of asthma that is characterized by neu-
trophilic or paucigranulocytic airway inflammation and 
may consist of: obesity-related asthma, late-onset; asthma 
and chronic obstructive pulmonary disease overlap syn-
drome (ACO)/neutrophilic, late-onset; smoking-related 
asthma; paucigranulocytic, associated with smooth mus-
cle. Pulmonologist need to perform a rigorous selection 
of patients candidate for BT, should follow a step-by-step 
assessment from difficult to severe asthma (Table I). Pa-
tients with severe steroid-resistant refractory asthma may 
also be selected for BT.27 moreover, BT was considered 
as a preferential treatment for patients who could not be 
Table I.— Indications BT.
inclusion criteria
1. Patient with severe persistent asthma uncontrolled found stable for at 
least 3 weeks
2. Patient receiving regular treatment with inhaled corticosteroids 
(beclomethasone >1000 mcg or equivalent) and LABA (salmeterol 
≥100 mcg or equivalent)
3. aQLQ Score <6.25
4. FEV1 ≥50% predicted
5. Patients not smoking for at least one year
Exclusion criteria
1. acute asthma life threatening
2. concomitant respiratory diseases (e.g., cOPd or emphysema)
3. Use of ß-blocker drugs
4. Severe active infection in the last 2 weeks
5. Pacemaker, internal defibrillator or other implanted electronic device
6. Known sensitivity to medications used to perform bronchoscopy, 
including lidocaine, atropine and benzodiazepines
7. Currently known bleeding disorder is not well controlled
8. Inability to stop prior to the procedure taking anticoagulants, 
antiplatelet agents, aspirin or non-steroidal anti-inflammatory drugs
9. <18 years old
10. Pregnant women
Table II.— Check-list for the procedure.
On the day of the procedure
• Check asthma stable and no infection in the past 2 weeks.
• Check spirometry is above 55% predicted post salbutamol
• Check consent form signed for bronchoscopy.
• nebulized salbutamol 2.5 mg
• atropine 0.6 mg prior to procedure
• Sedation with midazolam, propofol and remifentanil in spontaneous 
breathing or as advised by anesthetist
• Local anesthesia of nose and throat
• Perform procedure
• Use 1-2 liters of oxygen during procedure
• Monitor oxygen saturation, ECG and blood pressure
• ensure arrest trolley available
after procedure
• Monitor oxygen saturation, blood pressure and pulse every 15 minutes 
for the first hour and then every 30 minutes for the next 4 hours.
• Check asthma stable before sending home. To be checked by respiratory 
physician.
• repeat spirometry [PFT lab]
• instruction sheet, prescription for antibiotics if present sign of infection, 
asthma clinic appointment 2 weeks where next procedure will be 
booked if patient stable. Contact details of hospital center, prednisolone 
treatment
• Prescription for antibiotics if present sign of infection, asthma clinic 
appointment 2 weeks where next procedure will be booked if patient 
stable.
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general anesthesia administered by an anesthesiologist. 
Usually, patient is hospitalized a day before procedure and 
discharged when patient is considered stable with an aver-
age duration of hospital stay of 3-4 days. Table ii illustrates 
the check-list for the procedure. Patients are treated with 
50 mg/day of prednisolone or equivalent for 5 days, start-
ing treatment 3 days prior to the procedure. The procedure 
consists in the treatment of right lower lobe for first, left 
lower lobe during second session and right and left upper 
lobe in last session. Sessions are performed every three or 
four weeks. All accessible airways are treated with the ex-
ception of the right middle lobe, because of the theoretical 
concern of inducing right middle lobe syndrome. Before 
starting procedure bronchoscopist performs an inspection 
of the region of the lung that is to be treated and plans the 
order in which the airway segments are to be accessed and 
treated. The bronchoscopist reach the distal bronchi with 
the area to treat in clear view. The catheter is subsequently 
introduced in the working channel of the bronchoscope up 
Core basic skills
Bronchial thermoplasty should only be performed by pul-
monologists experienced in bronchoscopy and staff may 
be involve 2 trained endoscopy and nurses to handle the 
basket catheter and support the patient. Furthermore, it is 
crucial an experienced anesthetist in management of anes-
thesia/sedation protocol. Pulmonologist should have com-
petence in flexible and rigid bronchoscopy and basic biop-
sy technique such as endobronchial biopsy, transbronchial 
biopsy, TBna, rOSe, BaL and brushing. Pulmonologist 
must perform a proficiency training in the specific use of 
the alair™ Bronchial Thermoplasty System.
Procedural steps
BT is performed via fiberoptic bronchoscope inserted 
through the nose or mouth. The procedure is usually per-
formed with the patient under moderate sedation or light 
Figure 3.—BT is performed by a BT-certified pulmonologist in three outpatient visits, typically scheduled three weeks apart.
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typing and phenotyping of disease, as well as a compe-
tence in the management of severe asthma patients. are 
recommended overview of asthma pathophysiology and 
knowledge of bronchial anatomy. Training should include 
a review of alair™ System catheter directions for Use 
and Controller Operator’s Manual, guided didactic in-
struction in computer simulation-based Bronchial Ther-
moplasty Learning centre, detailed in-service training of 
the alair™ System. Hands-on training with alair™ System 
in a lung model prior to initial cases, proctoring of initial 
cases by Boston Scientific Health Care Industry Represen-
tative (Hcir). Ongoing support of cases is provideo when 
requested Physicians may undergo training through an ac-
credited program of alair™ delivery with Boston Scientific 
(the applicant) under the supervision of a qualified proc-
tor. Training is provided free of charge. The service should 
only be provided by an interventional pulmonologist or a 
respiratory physician.
We also suggest the use of plastic and animal models 
to simulate the procedure. moreover, good practical train-
ing on bronchial thermoplasty need to perform at least 5 
supervised procedures, live session and clinical cases for 
problems discussion with emphasis on the strategy to be 
followed in different situations. To assess and manage 
complications that may occur before, during and after 
bronchial thermoplasty, it may be useful to elicit non-tech-
nical skill with simulation in a contest of multidisciplinary 
team with anesthetic physicians, nurses and pneumolo-
gists.
to first site to treat. Each bronchus is treated along its en-
tire visible length, with each activation targeting a 5-mm 
section of bronchus between 3 and 10 mm in diameter, 
beginning at the periphery and moving proximally. Areas 
should not be retreated. On average treatment consists of 
~30–70 activations per lobe (depending on the specific 
anatomy) and typically it takes 30-40 minutes to complete 
the procedure (Figure 3).
during this meticulous procedure, physician is sup-
ported by a partner with an airway mapping useful to reg-
ister the area already treated. Bronchial thermoplasty re-
quires close attention by the bronchoscopist to identify any 
marked effect on the bronchial mucosa except a transient 
blanching represented by a whitening of the mucosa. This 
makes it difficult to identify the treated bronchi (Figure 4).
during this endoscopic procedure may occur several 
events such as abundant secretions or uncontrollable cough, 
and bronchial mucosa of asthma patient is often friable and 
bloody due to hyperresponsiveness and chronic steroid 
therapy. This is why carrying out bronchial thermoplasty re-
quires expertise not only in interventional pulmonology but 
also in asthma management. in addition, an accurate pre-
screening of patients seems to be crucial in order to select 
the appropriate patient to offer the best treatment possible.
Theoretical and practical training
The trainee is required to have an extensive and updated 
knowledge of severe asthma both concerning new endo-
Figure 4.—Continuous activation with the catheter in the airway. A) Basket catheter inserted distally into the airway: electrodes expanded and gen-
erator activated; B) electrodes partially collapsed and retracted 5 mm distal to the previous activation; C) electrodes again expanded, with adjacent 
but not overlapping activation; D) electrodes partially collapsed and retracted 5 mm distal to the previous activations; E) electrodes again expanded, 
with adjacent but not overlapping activation.
a dB ec
P
R
O
O
F
M
IN
ER
VA
M
ED
IC
A
PROFF ID.indd   1 10/09/10   14:28
FacciOLOnGO  cOmPeTence in BrOncHiaL THermOPLaSTY
428 Panminerva medica September 2019 
et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 
1997;100:44–51. 
14. Lauzon AM, Martin JG. Airway hyperresponsiveness; smooth muscle 
as the principal actor. F1000 res 2016;5:F1000 Faculty rev-306. 
15. Noble PB, Pascoe CD, Lan B, Ito S, Kistemaker LE, Tatler AL, et al. 
Airway smooth muscle in asthma: linking contraction and mechanotrans-
duction to disease pathogenesis and remodelling. Pulm Pharmacol Ther 
2014;29:96–107. 
16. Woodruff PG, dolganov Gm, Ferrando re, donnelly S, Hays Sr, 
Solberg Od, et al. Hyperplasia of smooth muscle in mild to moderate 
asthma without changes in cell size or gene expression. Am J Respir Crit 
care med 2004;169:1001–6. 
17. Carroll N, Elliot J, Morton A, James A. The structure of large 
and small airways in nonfatal and fatal asthma. am rev respir dis 
1993;147:405–10. 
18. Nair P, Martin JG, Cockcroft DC, Dolovich M, Lemiere C, Boulet LP, 
et al. airway Hyperresponsiveness in asthma: measurement and clinical 
Relevance. J Allergy Clin Immunol Pract 2017;5:649–659.e2. 
19. Danek CJ, Lombard CM, Dungworth DL, Cox PG, Miller JD, Biggs 
MJ, et al. reduction in airway hyperresponsiveness to methacholine by the 
application of RF energy in dogs. J Appl Physiol (1985) 2004;97:1946–53. 
20. Panettieri RA Jr, Kotlikoff MI, Gerthoffer WT, Hershenson MB, 
Woodruff PG, Hall iP, et al.; national Heart, Lung, and Blood institute. 
Airway smooth muscle in bronchial tone, inflammation, and remodel-
ing: basic knowledge to clinical relevance. Am J Respir Crit Care Med 
2008;177:248–52. 
21. Panettieri RA Jr, Kotlikoff MI, Gerthoffer WT, Hershenson MB, 
Woodruff PG, Hall iP, et al.; national Heart, Lung, and Blood institute. 
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menzella F, et al. nerve ablation after bronchial thermoplasty and sus-
tained improvement in severe asthma. Bmc Pulm med 2018;18:29. 
25. Pretolani M, Bergqvist A, Thabut G, Dombret MC, Knapp D, Hamidi 
F, et al. effectiveness of bronchial thermoplasty in patients with severe 
refractory asthma: clinical and histopathologic correlations. J Allergy Clin 
immunol 2017;139:1176–85. 
26. Denner DR, Doeing DC, Hogarth DK, Dugan K, Naureckas ET, 
White SR. Airway Inflammation after Bronchial Thermoplasty for Severe 
asthma. ann am Thorac Soc 2015;12:1302–9. 
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28. menzella F, Lusuardi m, Galeone c, Facciolongo n. Bronchial ther-
moplasty and the role of airway smooth muscle: are we on the right direc-
tion? Ther Clin Risk Manag 2017;13:1213–21. 
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Quantitative e qualitative assessment
The final assessment includes:
• quantitative assessment:
• number of procedures, at least 3 procedures under 
supervision
• qualitative assessment:
• mcQ
• case-based questionnaires
• dOPS
• outcome assessment: mortality, survival, complications, 
pulmonary function, quality of life, dyspnea scores, average 
duration of procedure: 30-45 minutes per session.30, 31
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